Acumen shareholders elect three Class I directors, ratify EY as auditor

Acumen Pharmaceuticals, Inc.

Elected Kimberlee C. Drapkin, Jeffrey Ives, and Sean Stalfort as Class I directors until 2028 with ~30M votes each; ~17.5M broker non-votes.
Ratified Ernst & Young as independent auditor for FY2025: 51.4M for, 118,735 against, 35,514 abstain.
Approximately 85% of outstanding shares (51.5M of 60.6M) were present or represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.